533 related articles for article (PubMed ID: 27647273)
1. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.
Hartmanshenn C; Scherholz M; Androulakis IP
J Pharmacokinet Pharmacodyn; 2016 Oct; 43(5):481-504. PubMed ID: 27647273
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.
Tylutki Z; Mendyk A; Polak S
J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):663-677. PubMed ID: 29943290
[TBL] [Abstract][Full Text] [Related]
3. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine.
Marsousi N; Desmeules JA; Rudaz S; Daali Y
J Pharm Sci; 2017 Sep; 106(9):2380-2391. PubMed ID: 28456730
[TBL] [Abstract][Full Text] [Related]
5. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
6. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
Johnson TN; Rostami-Hodjegan A
Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
[TBL] [Abstract][Full Text] [Related]
8. The Promises of Quantitative Proteomics in Precision Medicine.
Prasad B; Vrana M; Mehrotra A; Johnson K; Bhatt DK
J Pharm Sci; 2017 Mar; 106(3):738-744. PubMed ID: 27939376
[TBL] [Abstract][Full Text] [Related]
9. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
[TBL] [Abstract][Full Text] [Related]
10. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).
Vizirianakis IS; Mystridis GA; Avgoustakis K; Fatouros DG; Spanakis M
Oncol Rep; 2016 Apr; 35(4):1891-904. PubMed ID: 26781205
[TBL] [Abstract][Full Text] [Related]
11. Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics.
Howard M; Barber J; Alizai N; Rostami-Hodjegan A
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1315-1330. PubMed ID: 30465453
[TBL] [Abstract][Full Text] [Related]
12. Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM
Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949
[TBL] [Abstract][Full Text] [Related]
13. Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview.
Jia Q; He Q; Yao L; Li M; Lin J; Tang Z; Zhu X; Xiang X
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557804
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.
Kim YH; Kang P; Cho CK; Jung EH; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
Arch Pharm Res; 2021 Jul; 44(7):713-724. PubMed ID: 34304363
[TBL] [Abstract][Full Text] [Related]
15. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetic (PBPK) modeling in children.
Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B
Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290
[TBL] [Abstract][Full Text] [Related]
17. Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients.
Kovar L; Weber A; Zemlin M; Kohl Y; Bals R; Meibohm B; Selzer D; Lehr T
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32977559
[TBL] [Abstract][Full Text] [Related]
18. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.
Li M; Zou P; Tyner K; Lee S
AAPS J; 2017 Jan; 19(1):26-42. PubMed ID: 27834047
[TBL] [Abstract][Full Text] [Related]
19. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
Bouzom F; Ball K; Perdaems N; Walther B
Biopharm Drug Dispos; 2012 Mar; 33(2):55-71. PubMed ID: 22228149
[TBL] [Abstract][Full Text] [Related]
20. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification.
Krauss M; Burghaus R; Lippert J; Niemi M; Neuvonen P; Schuppert A; Willmann S; Kuepfer L; Görlitz L
In Silico Pharmacol; 2013; 1():6. PubMed ID: 25505651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
